New drug cocktail aims to tame a common blood cancer
NCT ID NCT07555470
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study is testing a combination of two drugs, mosunetuzumab and zeprumetostat, in about 80 people with follicular lymphoma, a type of blood cancer. The trial includes patients who are newly diagnosed (with high or low tumor burden) and those whose cancer has come back or stopped responding to treatment. The goal is to see if the combination can shrink tumors and delay the cancer from getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mosunetuzumab and Zeprumetostat (SHR2554)
What this could lead to
If successful, this combination could offer a more effective treatment option for follicular lymphoma, potentially leading to longer remission without the need for chemotherapy.
What could go wrong
This is an early-phase trial with only 80 participants, so results may not apply to all patients. The combination may cause side effects, and it is not yet known if it will work better than existing therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGTianjin, China
Contact